100 / 1631
Nivolumab in R/R HL (CA-209-039):
Initial Responses and Response Duration
cHL (n = 23)
76 Weeks
Overall response, n (%)
20 (87)
Partial response rate, n (%)
15 (65)
Complete response rate, n (%)
5 (22)
24-week progression-free survival, %
87%
Duration of response, median (range)
NR (18–82+)
Ansell SM, et al.
N Engl J Med.
2015;372(4):311-319.
R/R, relapsed or refractory
Phase I trial of nivolumab in patients with relapsed or refractory cHL